CO6280489A2 - (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina - Google Patents

(r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina

Info

Publication number
CO6280489A2
CO6280489A2 CO10092662A CO10092662A CO6280489A2 CO 6280489 A2 CO6280489 A2 CO 6280489A2 CO 10092662 A CO10092662 A CO 10092662A CO 10092662 A CO10092662 A CO 10092662A CO 6280489 A2 CO6280489 A2 CO 6280489A2
Authority
CO
Colombia
Prior art keywords
propionamide
phenyl
crystalline
cyclopropansulphonyl
tetrahydropiran
Prior art date
Application number
CO10092662A
Other languages
English (en)
Inventor
Jeanette Dunlap
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6280489(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6280489A2 publication Critical patent/CO6280489A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a R-2-(4- ciclopropansulfonil-fenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina, y a métodos para su preparación y uso.1.- R-2-(4-ciclopropansulfonil-fenil)-N-pirazin-2-il-3-(tetrahidropiran-4-iI)-propionamida en forma cristalina, caracterizada por una configuración de difracción en polvo de rayos X de una fuente de CuKα (λ=1.54056 Å) que comprende picos a: a) 11.5° y 19.0°+/-0.1° en 2θ o; b) 11.5°, 17.1°, 19.0°, y 26.6° +/- 0.1°en 2θ; o c) 11.5°, 17.1°, 19.0°, 26.6°, 9.4°, 15.0 +/- 0.1°, 16.5° +/- 0.1°, y 20.7° +/- 0.1° en 2θ.
CO10092662A 2008-01-15 2010-07-29 (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina CO6280489A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2113308P 2008-01-15 2008-01-15

Publications (1)

Publication Number Publication Date
CO6280489A2 true CO6280489A2 (es) 2011-05-20

Family

ID=40451065

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10092662A CO6280489A2 (es) 2008-01-15 2010-07-29 (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina

Country Status (22)

Country Link
US (1) US20090181981A1 (es)
EP (1) EP2265271A1 (es)
JP (1) JP2011509934A (es)
KR (1) KR20100092061A (es)
CN (1) CN101909629A (es)
AR (1) AR070107A1 (es)
AU (1) AU2009205606A1 (es)
BR (1) BRPI0907165A2 (es)
CA (1) CA2712245A1 (es)
CL (1) CL2009000004A1 (es)
CO (1) CO6280489A2 (es)
DO (1) DOP2010000216A (es)
EA (1) EA201070853A1 (es)
EC (1) ECSP10010347A (es)
IL (1) IL206102A0 (es)
MA (1) MA31985B1 (es)
MX (1) MX2010007784A (es)
PE (1) PE20091313A1 (es)
TN (1) TN2010000299A1 (es)
TW (1) TW200934772A (es)
WO (1) WO2009091634A1 (es)
ZA (1) ZA201003909B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101588466B1 (ko) 2007-08-22 2016-01-25 아스트라제네카 아베 시클로프로필 아미드 유도체
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
NZ602108A (en) * 2010-02-18 2014-09-26 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
MX2012009473A (es) 2010-02-18 2012-09-12 Astrazeneca Ab Procesos para preparar derivados de ciclopropilamidas e intermedios asociados con estas.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101220371B1 (ko) 2010-09-17 2013-01-09 현대자동차주식회사 베인펌프
WO2012108473A1 (ja) * 2011-02-08 2012-08-16 国立大学法人高知大学 カルサイト単結晶の製造方法
JP2013014534A (ja) * 2011-07-04 2013-01-24 Daicel Corp ベンゾイルギ酸化合物、及びその製造方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046768A (en) * 1976-06-17 1977-09-06 Velsicol Chemical Corporation 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
WO2001083465A2 (en) * 2000-05-03 2001-11-08 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
US6489485B2 (en) * 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
MXPA02010796A (es) * 2000-05-08 2003-03-27 Hoffmann La Roche Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa.
AU2001287600B2 (en) * 2000-07-20 2006-07-13 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
BR0115999A (pt) * 2000-12-06 2003-09-30 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
US6911545B2 (en) * 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
AU2005235798A1 (en) * 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
KR20080105180A (ko) * 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
EP1948645A1 (en) * 2005-11-03 2008-07-30 Prosidion Limited Tricyclo substituted amides

Also Published As

Publication number Publication date
BRPI0907165A2 (pt) 2015-07-14
TW200934772A (en) 2009-08-16
CN101909629A (zh) 2010-12-08
CA2712245A1 (en) 2009-07-23
AU2009205606A1 (en) 2009-07-23
JP2011509934A (ja) 2011-03-31
IL206102A0 (en) 2010-11-30
DOP2010000216A (es) 2010-10-15
KR20100092061A (ko) 2010-08-19
AR070107A1 (es) 2010-03-17
EP2265271A1 (en) 2010-12-29
MX2010007784A (es) 2010-08-09
EA201070853A1 (ru) 2010-12-30
CL2009000004A1 (es) 2010-02-19
MA31985B1 (fr) 2011-01-03
WO2009091634A1 (en) 2009-07-23
US20090181981A1 (en) 2009-07-16
ECSP10010347A (es) 2010-09-30
PE20091313A1 (es) 2009-09-03
TN2010000299A1 (en) 2011-11-11
ZA201003909B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
CO6280489A2 (es) (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
FI3351539T3 (fi) Kiteinen monohydraattikompleksi 1-syaani-2-(4-syklopropyylibentsyyli)-4-(ß-D-glukopyranos-1-yyli)bentseenistä ja L-proliinista kidevedessä (1:1:1), menetelmät sen valmistamiseksi ja sen käyttö SGLT-estäjänä
RS51954B (en) CRYSTAL MODIFICATIONS OF PYRACLOSTROBIN
AR082804A1 (es) Formas cristalinas de un inhibidor del factor xa
PH12015502825A1 (en) Crystals
CU20120122A7 (es) Derivados 5-aril-1,2,4-triazolona ligada a bisarilo sustituidos
CA2875877C (en) Syk inhibitors
NZ592504A (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
RU2015112098A (ru) Кристаллы производных диспиропирролидина
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
WO2008101682A3 (en) Iminipyridine derivatives and their uses as microbiocides
WO2009024342A3 (en) Novel microbiocides
AR088755A1 (es) Formas solidas de un inhibidor de disociacion transtiretina
MY185130A (en) Romidepsin solid forms and uses thereof
RS53415B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
ZA201108618B (en) Stable topical compositions for 1,2,4-thiadiazole derivatives
TR201902435T4 (tr) DGAT1 inhibitör içeren farmasötik bileşimler.
CO6630130A2 (es) Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino
RS53057B (en) NEW CRYSTAL FORM 3- (difluoromethyl) -1-methyl-N- (3`, 4`, 5`-trifluoro [1,1`-biphenyl] -2-yl) -1H-pyrazole-4-carboxamide
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
AR076856A1 (es) Lenalidomida polimorfa y proceso para su preparacion
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
WO2015042414A8 (en) Multicyclic compounds and methods of using same

Legal Events

Date Code Title Description
FA Application withdrawn